Traditional MedicarePrior AuthMedium impact
MolDX: Molecular Testing for Solid Organ Allograft Rejection
Medicare/CMS - LCD·Transplant Surgery, Nephrology, Cardiothoracic Surgery·Local Coverage Determination
Effective date
Aug 30, 2026
We identified it
Jul 16, 2026
Summary
This is a NEW Local Coverage Determination (LCD L40058) from Palmetto GBA establishing coverage criteria for molecular testing (MolDX) to detect solid organ allograft rejection. The policy becomes effective 8/30/2026 and applies to Medicare Part A and Part B beneficiaries. Billing teams must implement prior authorization requirements and ensure molecular rejection testing claims comply with the specified medical necessity criteria.
Action Required
By August 29, 2026: (1) Billing team must contact Palmetto GBA to obtain specific CPT/HCPCS codes for molecular organ rejection testing covered under LCD L40058, as the policy text provided does not list specific codes. (2) Update billing system with prior authorization rules requiring providers to submit medical necessity documentation before billing molecular rejection tests. (3) Notify transplant surgeons, nephrology, and cardiothoracic surgery providers of new prior auth workflow. (4) Create internal checklist for required documentation (patient diagnosis, organ type, clinical indication). (5) Train front-desk and billing staff on the new authorization process. Claims submitted without prior authorization or incomplete medical necessity documentation will be denied effective 8/30/2026.